AUTHORS
Steven Sher, MD, PhD, Omar Elghawy, MD2, Colin J. Thomas, MD3, Kimberly Carlton, RN4, Jordan S Carter, MD5, Elise A. Chong, MD6, Daniel Landsburg, MD7, Joshua D Brandstadter, MD,PhD,MSc8, Michael R Cook, MD9, Stephen J Schuster, MD10, Jakub Svoboda, MD11, Emily B. Tomasulo, DO12, Sunita Dwivedy Nasta, MD, MS13, Marco Ruella, MD14, Stefan K Barta, MD15
AFFILIATIONS
1 University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Introduction: T-cell lymphomas encompass a biologically diverse group of malignancies for which no single treatment regimen has proven broadly effective. Bexarotene, an oral retinoid X receptor agonist approved for cutaneous T-cell lymphoma (CTCL), acts through nuclear receptor–mediated induction of apoptosis and cellular differentiation. Despite the rationale for broader applicability, data on its activity across the spectrum of T-cell malignancies remain limited. Our group previously described a cohort of 12 patients with peripheral T-cell lymphomas (PTCL) treated with bexarotene between 2005-2016. We report updated outcomes of a larger cohort of patients (pts) (n=38) treated with bexarotene-containing regimens across PTCLs at the University of Pennsylvania.
Methods: We performed a single-center retrospective study of pts diagnosed with PTCL at the University of Pennsylvania between January 2010 and January 2026. Pts treated with bexarotene at any point during their disease course were included. Baseline demographic, disease, treatment, and outcome data were abstracted from the medical record. Treatment response was assessed using Lugano criteria. Co-primary endpoints, overall survival (OS) and progression-free survival (PFS), were estimated using Kaplan-Meier methods.
Results: Thirty-eight pts met inclusion criteria. Median age at diagnosis was 68.1 years [range 21.4–89.7], and 20/38 (52.6%) were male. Race was 68.4% Caucasian, 18.4% Black, and 13.2% other. The most common subtypes were T-follicular helper lymphoma (18, 47.4%), PTCL, not otherwise specified (16, 42.1%), and adult T-cell leukemia/lymphoma (2, 5.3%). Most patients (35/38, 92.1%) had stage III/IV disease at diagnosis and lactate dehydrogenase above the upper limit of normal (35/38, 92.1%), with 6 patients (15.8%) having bulky disease (>7.5 cm) at time of diagnosis. Absolute lymphocyte counts at diagnosis were available for 25/38 patients, with a mean of 2.15 ×10⁹/L. Most patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (31/38, 81.6%) and a high-risk International Prognostic Index score (26/38, 68.4%).
There were 20/38 (52.6%) patients treated in the frontline setting with bexarotene. In the frontline setting, the overall response rate (ORR) was 40% (8/20, 4 complete responses [CR], 4 partial responses [PR]). Median progression-free survival (mPFS) and median overall survival (mOS) for patients treated in the frontline were 5.2 months [95% confidence interval (CI), 2.9-18] and 38 months [95% CI, 4.8-84], respectively. The remaining 18/38 (47.4%) patients received bexarotene as part of their treatment protocols in either the second, third, fourth, or fifth line of therapy. Of these, 17/18 (94.4%) had evaluable disease state, with 4 CRs and 2 PRs, for an ORR of 35.2% (6/17). No patients proceeded to autologous transplant after treatment with bexarotene.
Median duration of follow-up was 31.5 months [range 0.73-212.4]. mPFS and mOS for the whole cohort were 8.1 months [95% CI, 5.8-11] and 32 months [95% CI, 13-84] respectively. There was no difference in either progression-free survival or overall survival in patients treated with bexarotene in the frontline and non-frontline settings. Improved OS and PFS were noted among patients with ECOG 0-1 compared to higher ECOG statuses (log-rank p < 0.05). Three patients (3/38, 7.9%) stopped treatment with bexarotene due to side effects, although no grade 3 or higher side effects were reported. Ten patients (10/38, 26.3%) were alive at last follow-up, with 26.3% of the cohort lymphoma-free at that time. Causes of death for the entire cohort were infection (13/38, 34.2%), lymphoma (11/38, 28.9%), and unspecified or unknown causes (4/38, 10.5%).
Conclusion: This study shows that bexarotene-containing regimens can induce disease responses in both the frontline and relapsed/refractory settings across multiple T-cell malignancy subtypes in select patients, with comparable survival outcomes regardless of treatment line. As with our prior work, bexarotene was associated with response among even patients who were heavily pretreated. These findings support further investigation of bexarotene's role across the T-cell lymphoma spectrum, beyond its current CTCL-focused approval. Better understanding of its exact mechanism of action and potential predictive biomarkers is needed to identify patients who may derive benefit of bexarotene as well as prospective evaluation of its single-agent efficacy.
DISCLOSURES
Steven Sher, MD, PhD: DNA Nanobots - Consultancy (Includes expert testimony)